Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Earnings History
Profitable2 years of earnings data (2024–2025) · Positive TTM net income
Loading earnings history...
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Earnings Overview
As of November 8, 2026, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) reported trailing twelve-month net income of $7M, reflecting +439.3% year-over-year growth. The company earned $0.29 per diluted share over the past four quarters.
Looking at the long-term picture, DMAA's historical earnings data spans multiple years. The company achieved its highest annual net income of $6M in fiscal 2025, representing a new all-time high.
Drugs Made In America Acquisition Corp. Ordinary Shares maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including HCAI (N/A net income, -659.2% margin), BRTX (-$11M net income, -3959.4% margin), NUVB (-$136M net income, -325.3% margin), DMAA has comparable earnings metrics. Compare DMAA vs HCAI →
DMAA Earnings vs Peers
Earnings metrics vs comparable public companies
DMAA Historical Earnings Data (2024–2025)
2 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6M | +1240317.7% | -$3M | $0.19 | - | - |
| 2024 | $-479 | - | $-479 | $-0.06 | - | - |
Download Data
Export DMAA earnings history in CSV or JSON format
Free sign-in required to download data
DMAA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DMAA — Frequently Asked Questions
Quick answers to the most common questions about buying DMAA stock.
What is DMAA earnings per share (EPS)?
DMAA trailing twelve-month (TTM) diluted EPS is $0.29, reflecting +439.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2024 to 2025 is available in the table on this page.
What is Drugs Made In America Acquisition Corp. Ordinary Shares's net income?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) trailing twelve-month net income is $7M as of 2025. Earnings grew +439.3% year-over-year.
Is DMAA profitable?
Yes, DMAA is profitable with a TTM net income of $7M and a net profit margin of N/A.
What is DMAA's earnings growth rate?
DMAA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2024 to 2025.
What are DMAA's profit margins?
Drugs Made In America Acquisition Corp. Ordinary Shares net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is +5.1%.
Is DMAA growing earnings?
Yes, DMAA earnings are accelerating — EPS growth of +439.3% exceeds the 5-year CAGR of N/A. TTM net income reached $7M. Earnings momentum is strengthening.
What was DMAA's best earnings year?
Drugs Made In America Acquisition Corp. Ordinary Shares's highest annual net income on record is $6M, achieved in fiscal year 2025. Earnings history on this page spans 2024 to 2025 and includes all annual and quarterly figures.
What were DMAA's earnings last quarter?
DMAA's most recent reported quarter was Q1 2026. Net income was $2M with diluted EPS of $0.06. For a full breakdown of all quarters, see the quarterly earnings table on this page.